Conflicting Triptan Data Leaves Clinicians Guessing

Generated October 2026 · Clinical Deep Dive0 CommentsA 2025 cohort found no excess cardiovascular risk with triptans. Another 2026 analysis found that initiation carries a hazard ratio (HR) of 2.37 for ischemic stroke. You’re probably seeing patients caught in the middle.The 2026 analysis covered 869,092 US patients. It put the absolute risk difference at 0.17% per year (J Am Heart Assoc). A 2025 Israeli cohort of 26,054 patients found no excess cardiovascular risk, even with risk factors present (adjusted HR, 0.96; 95% CI, 0.77-1.23) (Headache). The sumatriptan label, most recently revised in December 2025, still carries the same cardiovascular contraindications (FDA label). Contraindications Base Risk on Mechanism, Not Clinical Outcome TrialsNo randomized trial has been powered to detect cardiovascular harm from triptans in patients with established cardiovascular disease (JAMA Neurology).The regulatory warnings stem from a pharmacologic mechanism. Triptans act as 5-HT1B/1D agonists, and their vasoconstrictive properties raised concern that they could affect coronary and peripheral vascular beds, although in vivo data show minimal or no vasoconstriction of cerebral arteries in patients with migraine (JAMA Neurology).The label lists several absolute contraindications; the six cardiovascular, electrophysiological, and vascular ones are:Ischemic coronary artery disease or coronary vasospasmWolff-Parkinson-White syndrome or other accessory pathway disordersStroke, transient ischemic attack (TIA), or hemiplegic/basilar migraine historyPeripheral vascular diseaseIschemic bowel diseaseUncontrolled hypertensionAccording to FDA product labeling, these cardiovascular, electrophysiological, and vascular conditions represent formal contraindications to triptan therapy (FDA label). Clinical guidelines, including the 2023 Veterans Affairs/Department of Defense (VA/DoD) Clinical Practice Guideline, support these restrictions while noting that de novo coronary vasospasm in individuals without underlying cardiovascular disease is exceedingly rare (VA/DoD CPG).Because clinical trials routinely exclude patients with established cardiovascular disease due to labeling restrictions, definitive safety data in this specific population are lacking.Observational Data Show Conflicting Cardiovascular Risk SignalsObservational studies with neutral findings. The 2025 Clalit cohort found no statistically significant association between triptan use and cardiovascular events, including across sensitivity analyses examining exposure windows, use patterns, and individual triptans (HRs, 0.79-1.07) (Headache). Similarly, a 2020 Kaiser Permanente Southern California cohort study of 189,684 patients reported no increased risk of composite cardiovascular outcomes (composite HR, 0.99; 95% CI, 0.93-1.06) (Headache).Observational studies reporting elevated risk. In contrast, a 2026 US health claims analysis of 869,092 patients reported increased hazard ratios following triptan initiation:Ischemic stroke: HR, 2.37 (95% CI, 1.65-3.51)Myocardial infarction (MI): HR, 2.06 (95% CI, 1.60-2.66)Intracranial hemorrhage: HR, 2.37 (95% CI, 1.65-3.41) (J Am Heart Assoc) Because this was a retrospective claims analysis, these associations, including the intracranial hemorrhage finding, do not establish that triptans cause these events. The authors offered several possible explanations for the hemorrhage association, including arterial wall stress from competing vasoconstrictive and vasodilatory effects, hemorrhagic transformation of ischemic stroke, and more intense migraine activity, and noted that residual confounding could also account for the increased risks of ischemic and hemorrhagic stroke (J Am Heart Assoc).A 2024 Danish case-crossover study of 429,612 first-time initiators found odds ratios of approximately 3 for ischemic stroke and myocardial infarction in the 14 days following initiation (JAMA Neurology). However, the study rested on a small number of absolute events (11 to 35 events per outcome), producing wide confidence intervals (eg, MI 95% CI, 1.0-10.9), and case patients had a median age of approximately 60 years and a high-risk cardiovascular profile (JAMA Neurology). Methodological Differences and Channeling BiasA primary source of debate among researchers is channeling bias, wherein clinicians selectively prescribe triptans to healthier individuals while withholding them from patients with cardiovascular risk factors. When selective prescribing occurs, observational studies may underestimate drug risk.Evidence of selective prescribing appears in the Clalit study data: Patients who were never prescribed a triptan had a higher baseline prevalence of measured cardiovascular risk factors (standardized mean differences up to 0.289) (Headache). The study authors also noted that the overall evidence on cardiovascular risk with triptans remains mixed (Headache).In the 2026 US cohort, the falsification control endpoint (humeral fracture) showed a lower hazard among triptan initiators (HR, 0.66; 95% CI, 0.58-0.76), suggesting they were at lower baseline medical risk. The authors interpreted this as residual confounding that biased the hazard ratios toward the null, a conservative property of the study. Other design features pulled in both directions: requiring initiators to remain event-free until their first prescription biased results toward the null, while not counting the pre-prescription period as exposed time biased them away from it. Because only a single falsification endpoint was used, other dimensions of residual confounding, such as frailty or healthcare use, could not be assessed (J Am Heart Assoc).Each observational study design has inherent analytical limitations. Propensity score methods cannot completely eliminate unmeasured confounding by indication, whereas case-crossover designs may lack generalizability if cases differ systematically from general treatment initiators. No consensus has emerged on how to reconcile these contrasting approaches.Analytical note: Evaluating baseline risk characteristics between treated and untreated groups helps identify potential channeling bias in observational cohort evaluations.Don’t Blend the Absolute-Risk NumbersThe Danish study reports a short-term attributable risk at first exposure, whereas the 2026 US cohort estimates an ongoing incidence difference of 0.17% per year in a broader longitudinal cohort (JAMA Neurology, J Am Heart Assoc). Because follow-up intervals and reference denominators differ across studies, absolute risk metrics should be evaluated individually within their specific study contexts.For patients without underlying cardiovascular risk factors, observational data indicate a low absolute risk (JAMA Neurology). The discrepancies across studies matter most for patients with existing cardiovascular risk factors.Clinical Management and Practice GuidelinesThree guidance documents apply, covering different populations and complementing one another. One or two risk factors, no established disease. The American Headache Society (AHS) 2021 consensus says drug selection “must be individualized” when contraindications aren’t clear-cut (Headache).Moderate calculated risk. A 2019 risk-stratification framework recommends noninvasive cardiac evaluation prior to prescribing triptans and advises against triptan use in higher-risk patients (Headache).History of stroke, cardiovascular disease, or uncontrolled hypertension. The 2024 International Headache Society (IHS) treatment recommendations outline a stepped approach: acetaminophen (paracetamol) first, followed by lasmiditan (Note: lasmiditan [Reyvow] was scheduled for market discontinuation; see availability note below) or a calcitonin gene-related peptide (CGRP) receptor antagonist (gepant). A triptan may be considered with caution only if these conditions are under control and earlier options have not helped, although the FDA label lists prior stroke and ischemic coronary artery disease as contraindications. Ergotamine and dihydroergotamine (DHE) should be avoided (Cephalalgia).The IHS guideline also suggests reserving triptans for patients in the optimal or normal blood pressure categories, given a modest pressor effect of 0 to 10 mmHg. It says age alone isn’t a contraindication (Cephalalgia).The FDA label recommends that triptan-naive patients with multiple cardiovascular risk factors undergo cardiovascular evaluation before starting therapy. After a negative evaluation, it suggests considering a supervised first dose accompanied by an ECG (FDA label).Triptans are also prescribed despite labeled contraindications: a 2022 claims analysis found that 13.9% of triptan-treated patients had at least one FDA-listed contraindication (Headache). Cardiovascular Safety Profiles of CGRP InhibitorsWhile CGRP-targeted therapies do not cause direct vasoconstriction, recent longitudinal data present additional safety considerations.In a 2026 study of 900,370 patients, CGRP inhibitor initiators demonstrated a higher incidence rate of composite cardiovascular events compared with non-initiators (8.77 vs. 6.76 events per 1,000 person-years; adjusted HR, 1.26; 95% CI, 1.10-1.45) (Neurology). Among individual endpoints, only ischemic stroke demonstrated a statistically significant increase when evaluated independently. However, patients initiating CGRP inhibitors had higher baseline cardiovascular risk profiles, suggesting that preferential prescribing to patients with vascular risk factors may account for part of the observed association (Neurology).A 2020 preclinical study suggested a potential mechanism involving CGRP's role in protective vasodilation during ischemic events (Annals of Neurology). However, because experimental animal doses exceeded clinical human doses by 10- to 100-fold, direct translation to human clinical risk remains uncertain.A 2025 review outlines clinical recommendations for CGRP-targeted agents in patients with vascular risk (Neurology):Pause CGRP-targeted therapy immediately after acute stroke or subarachnoid hemorrhage (SAH).After a stroke history, wait at least 3 months and decide on reinitiation individually.Avoid the class in small vessel disease or Raynaud phenomenon.Where treatment is indicated, gepants may be preferred over monoclonal antibodies due to their shorter half-lives.International clinical practice guidelines vary: The AHS and Taiwan Neurological Society permit gepant use in patients with triptan contraindications, whereas the German Migraine and Headache Society advises caution (Cephalalgia).Regarding treatment availability, Eli Lilly announced the global commercial discontinuation of lasmiditan for reasons unrelated to safety, with US supply anticipated through mid-2026 (Association of Migraine Disorders). That window has since passed, so clinicians should confirm current availability before applying headache society algorithms that include ditans.Pharmacovigilance: Worth Watching, Not Acting OnA 2025 FDA Adverse Event Reporting System (FAERS) pharmacovigilance study reported disproportionality signals for ischemic events with almotriptan (reporting odds ratio [ROR], 3.34), naratriptan (ROR, 2.96), and rizatriptan (ROR, 2.41), while sumatriptan had lower relative reporting rates (J Pain Res). Pharmacovigilance reporting systems can generate hypotheses but cannot prove causality or quantify absolute incidence. Separately, a WHO VigiBase analysis observed a reporting signal for spontaneous coronary artery dissection (SCAD) across the triptan class (J Am Coll Cardiol).Similar observational complexity exists for CGRP monoclonal antibodies. The FDA added a postmarketing warning for hypertension to erenumab labeling based on spontaneous safety reports (Headache). Conversely, a 2025 comparative cohort study of 108,019 new preventive therapy initiators found no increased risk of hypertension, myocardial infarction, or stroke among erenumab users compared with active control treatments (Headache). The study was funded by Novartis and Amgen, with seven authors employed by Amgen; observational cohort outcomes and spontaneous reporting databases address complementary safety questions.What Your Peers Are SayingTriptans “should be prescribed with caution, but they should not be seen as absolutely contraindicated” in older patients with prior stroke, myocardial infarction, or hypertension, said Anders Hougaard, MD, PhD, of Copenhagen University Hospital, in a May 2026 VJNeurology conference interview (VJNeurology).“The distinction between contraindications and general [cardiovascular] risk factors is critical,” wrote Ido Peles, MD, PhD, of the Soroka Medical Center, Ben-Gurion University of the Negev, and colleagues in a 2025 Headache paper on triptan use in patients with migraine (Headache, NeurologyLive). Patients “should be counseled about the potential for increased risk of cardiovascular and cerebrovascular events when initiating a triptan,” wrote Brian Mac Grory, MB BCh BAO, MHSc, of Duke University School of Medicine, and colleagues in a 2026 J Am Heart Assoc study of 869,092 patients with migraine (J Am Heart Assoc)The Bottom LineFor low-risk patients, absolute risk is small under every reading.For patients with cardiovascular risk factors or established disease, observational findings conflict. Labeled contraindications remain in effect, and individualized risk assessment is recommended.Gepants represent an alternative class when triptans are contraindicated, though observational safety monitoring remains ongoing. Lasmiditan has been announced for global discontinuation, so confirm its availability. Prospective trials or registries tracking triptan exposure in patients with established cardiovascular disease could provide clearer evidence on safety in high-risk populations.Medscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: Triptans and Cardio Risk: Conflicting Data Leaves Clinicians Guessing - Medscape- October 16, 2026.